The 14-day notice: how a compounding wind-down works in Denmark
The document is four pages. Three of them are about dates.
The archive
Page 152 of 170 of this archive, newest first.
Why people actually stop, in the order they actually stop
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
GIP was a failed target for thirty years. Then it was not.
A dual agonist is one molecule with two receptor activities. A co-formulation is two molecules in one pen. The coverage treats them as synonyms.
Why a dead-clean sterile filter can pass pyrogen straight through
Bacterial endotoxin is a heat-stable lipopolysaccharide from the outer membrane of Gram-negative organisms. It survives sterilisation, passes a sterilising filter, and is…
The quiet end of the relabeller trading as Vantris Bio
A proper account of an operation that existed, and of what closing it cost.
Independent analysis puts a GL Biochem tirzepatide lot at 96.7%, against 95.9% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
SURMOUNT-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
GIP was a failed target for thirty years. Then it was not.
What adding GIP activity does, on the current evidence, and what remains unresolved.
The relabeller trading as Vantris Bio closes after 3 years
A proper account of an operation that existed, and of what closing it cost.
PeptideMeter result on a Zhuhai cagrilintide lot lands 1.5 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Ireland pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Sarcopenia is a diagnosis, not a synonym for losing lean mass
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
The three-times-upper-limit convention, and where it came from
Asymptomatic pancreatic enzyme elevation is common on treatment and is not pancreatitis. The distinction is clinical, not biochemical.
Spain pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What a 13% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
How a release document is put together in a regulated plant
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
The advice is mostly reasonable. The certainty is not earned.
Grading six widely repeated claims against the studies actually behind them.
The 28-day notice: how a compounding wind-down works in Brazil
The document is four pages. Three of them are about dates.
Wuhan export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
South Africa health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Thiamine and the vomiting patient
Which markers are informative, which are confounded, and which move for reasons unrelated to nutrition.
What changed at MKM in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
From the floor in Shenzhen: 19 posters, one theme
Reported from the sessions, and from the two hours afterwards.